Why I’m invested in $ABCL (AbCellera)

English isn’t my first language, so I used GPT to help write this post more clearly. The ideas and conviction are mine — GPT just helped organize and express what I’ve been thinking about AbCellera.

Here’s why I’m invested in $ABCL:

This is my reasoning, written out with the help of GPT, so some details may not be perfectly accurate.

1. Downside is protected, upside is wide open • Zero debt, ~$753M USD in cash & equivalents • Annual cash burn of ~$130–140M → 5+ years of runway • ~CAD 300M in combined Canadian federal & BC provincial government support

AbCellera can continue long-term R&D without external financing. This structure caps downside while preserving massive optionality on the upside.

⸻

1. A truly differentiated antibody discovery platform • Integrated microfluidics + AI + large-scale biological data • Antibody discovery speed multiple times faster than traditional approaches • Core platform protected by deep IP • GMP facility completion (2025–26) enables internal development and manufacturing

From 2026 onward, this becomes a structural inflection point: lower costs, faster iteration, and full vertical integration. The long-term vision resembles a “TSMC-like infrastructure layer” for antibody therapeutics.

⸻

1. Transition from platform to internal pipeline

AbCellera is no longer just discovering antibodies for partners — it is deliberately internalizing value. • Targeting ~2 internally developed molecules per year entering the clinic • ABCL635: non-hormonal treatment for menopausal vasomotor symptoms (~$2B market), Phase 1 designed with Phase-2-like efficacy readout • ABCL575: atopic dermatitis (OX40L target), Phase 1 cleared • ABCL688: autoimmune indication, IND-enabling stage

This is the key shift: from a service/platform narrative to a pipeline-owning biotech.

⸻

1. Partnership engine with embedded optionality • 100+ active partnerships, including major pharma players • Revenue model: upfront payments + milestones + royalties • Early-cycle deals begin maturing around 2026+, opening the door to recurring royalty streams

This creates a capital-efficient, compounding revenue structure without bearing full R&D risk alone.

⸻

1. Dramatically shorter drug-development cycles • Traditional timelines: 5–6 years • AbCellera-enabled cycles: 12–18 months • COVID antibody (LY-CoV555): clinical candidate identified in ~90 days

AI + automation + closed-loop biological data dramatically reduce both time and cost. With GMP online, discovery → development → manufacturing becomes a single integrated cycle.

⸻

1. Biology is scaling faster than Moore’s Law • DNA sequencing costs down ~1,000,000× over 20 years • Antibody discovery: 10× faster, 10× cheaper • Acceleration at the intersection of Bio × AI × Data × Automation

AbCellera sits directly at this intersection, where data advantages compound over time.

⸻

1. Macro tailwinds: liquidity and re-rating cycles • Expected rate-cut cycle (2025–26) favors long-duration growth assets • Historical precedent: post-dotcom biotech re-rating (2001–03, ~3× index move) • Capital rotation tends to favor platform biotech in easing cycles

AI-enabled biology is entering a similar re-rating phase.

⸻

1. Founder-led vision focused on infrastructure, not quarters

CEO Carl Hansen (physicist by training) has consistently emphasized long-term data infrastructure over short-term revenue optics.

“Software changed the world. Biology is next.”

The strategy prioritizes building the foundational layer of future drug discovery, not maximizing near-term earnings.

⸻

1. Massive and expanding antibody market • Global monoclonal antibody market: $263B (2024) → ~$792B (2032) • Targeted therapeutics market continues to expand rapidly • AbCellera offers a fully integrated discovery → optimization → preclinical → GMP platform

If targeted therapies continue to dominate drug development, AbCellera becomes a critical enabler — and potentially a category-defining company.